Study of the drug acalabrutinib and antibody rituximab in patients with leukemia or
Is the combination of the drug acalabrutinib and antibody therapy, rituximab, safe
and effective in patients who have previously untreated chronic lymphocytic leukemia/small
lymphocytic lymphoma (CLL/SLL)?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
Despite an array of available therapies, chronic lymphocytic leukemia (CLL) remains
an incurable disease. The development of an improved therapy would be a major contribution
to the management of CLL and other B cell malignancies.
The investigator proposes that the drug acalabrutinib will work better with an antibody
treatment, rituximab, in the treatment of CLL.
Study Reference #: ULYM18086
Lead Researcher (Principal Investigator)
Lead Researcher: Paul Barr
Study Contact InformationStudy Coordinator: Andrew Bui
Phone: (585) 276-4405
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search